[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"menstrual-discomfort\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:menstrual-discomfort":33},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,58,84],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":41,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":57},"100628155","effectiveness-of-an-mhealth-innovation-on-the-impact-of-menstrual-complaints-in-adolescents-100628155",false,"NCT07457957","Effectiveness of an mHealth Innovation on the Impact of Menstrual Complaints in Adolescents","The Effectiveness of an mHealth Innovation on the Impact of Menstrual Complaints in Adolescents - A Randomised Controlled Trial","MGA","Inclusion Criteria:\n\n* Dutch, English, Turkish or Moroccan-Arabic speaking\n* Post menarche\n* Access to a smartphone or tablet with iOS or Android operating system\n\nExclusion Criteria:\n\n* Amenorrhea\n* Pregnancy\n* No menstrual bleeding or withdrawel bleeding in the 3 months prior to inclusion.\n* Previously or currently under treatment by a health care provider for menstrual complaints",true,"FEMALE","12 Years","21 Years",{"count":22,"type":23},874,"ESTIMATED","INTERVENTIONAL",[26],"NA","The aim of this study is to improve menstrual health-related quality of life in adolescents by using a mobile menstrual health tracker. We will perform a randomized controlled trial to evaluate the (cost)-effectiveness of this mHealth intervention.",[29,30,31,32,33,34,35,36,37,38,39,40],"Dysmenorrhea","Heavy Menstrual Bleeding","Menstrual Cramps","Menstrual Bleeding, Heavy","Menstrual Discomfort","Menstrual Cycle Abnormal","Menstrual Disorder","Menstrual Health","Mobile Application","mHealth","Menstrual Health Intervention","Adolescent",[42,38,43,40,44],"randomized clinical trial","Menstrual health","Menstrual Tracker App","NOT_YET_RECRUITING","2026-03-04",{"date":48,"type":49},"2026-03-09","ACTUAL",{"date":51,"type":23},"2026-02-16",{"date":53,"type":23},"2029-05-31",{"name":55,"class":56},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","OTHER",1,{"id":59,"slug":60,"hasResults":11,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":4,"eligibilityCriteria":64,"healthyVolunteers":17,"sex":18,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":4,"studyType":24,"phases":69,"briefSummary":70,"conditions":71,"keywords":72,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":4},"100574569","efficacy-of-cl22205-to-improve-menstrual-discomfort-and-quality-of-life-100574569","NCT06760988","Efficacy of CL22205 to Improve Menstrual Discomfort and Quality of Life","A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy of CL22205 to Improve Menstrual Discomfort and Quality of Life","Inclusion Criteria:\n\n* Oligomenorrheic females (Menstrual cycle duration between 36-45 days), aged between 25 and 35 years and with a Body Mass Index (BMI) between 20 to 29.9 kg\u002Fm2.\n* Subjects with maximum pain intensity ≥40 mm on a 100 mm VAS for at least 2 menstrual cycles before participating in the study.\n* Subjects with normal thyroid profile.\n* Subjects who are non-smokers and non-alcohol user.\n* Subject understands the study procedures and provides signed informed consent to participate in the study.\n* Females of childbearing potential who are sexually active must agree to use adequate non-hormonal contraception during the study.\n* Normal vital signs, including electrocardiogram (ECG) and laboratory evaluations (including clinical chemistry, hematology, and complete urinalysis) within the reference range for the testing laboratory or the results are deemed not clinically significant for inclusion into this study by the investigator.\n\nExclusion Criteria:\n\n* History of any gynaecological disorders which effects the study indication.\n* History of cerebrovascular disease, thrombo-embolic disorders, heart attack, or angina at any time or thrombophlebitis within the last 5 years, on anti-coagulant or anti-platelet drugs on a daily basis for any conditions.\n* Subjects who had any hormonal therapy, metformin or any other herbal products in the past 3 months.\n* Hypothyroidism, hyperthyroidism, hyperprolactinemia, Cushing's syndrome and congenital adrenal hyperplasia, following a special diet for the past 3 months, taking drugs affecting insulin sensitivity or lipid and hormonal profiles, including glucocorticoids, ovulation-stimulating drugs, anti-obesity, anti-diabetes, anti-hypertensive, anti-estrogenic, anti-androgenic during the last 3 months (except the usual drugs of the subjects).\n* Active gall bladder disease, gynaecological or breast surgery in the last 6 months.\n* Subjects underwent hysterectomy.\n* History of breast, endometrial, other gynaecological cancer at any time or other cancer within the last 5 years.\n* Pregnant and lactating mothers.\n* History of hypersensitivity reactions attributed to investigational product (IP) or its components or related products.\n* History of positive hepatitis, including Hepatitis B surface antigen or Hepatitis C virus (HCV) antibodies or subjects with human immunodeficiency virus (HIV) and \u002For syphilis.\n* History of clinically significant illness or any other medical disorder that may interfere with subject treatment, assessment or compliance with the protocol.\n* Participated in a clinical study with an investigational drug or biologic within the last 60 days.\n* Any condition that in opinion of the investigator, does not justify the subjects' participation in the study.\n* Subjects who are being treated for liver cancer or cirrhosis, chronic renal failure, congestive heart failure.\n* Subjects with a systemic disease including tuberculosis, leucosis, collagenosis, multiple sclerosis or other autoimmune diseases.\n* Subjects with a high blood pressure at screening (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥ 90 mmHg).\n* Consumption of recreational drugs (such as cocaine, methamphetamine, marijuana, etc.) or psychiatric drug users.","25 Years","35 Years",{"count":68,"type":23},80,[26],"The purpose of this study is to evaluate the efficacy of CL22205 to improve menstrual discomfort and quality of life in oligomenorrheic female subjects.",[33],[73],"Quality of life","2025-03-04",{"date":76,"type":49},"2025-03-07",{"date":78,"type":23},"2025-02-24",{"date":80,"type":23},"2026-01-10",{"name":82,"class":83},"Eetho Brands, Inc","INDUSTRY",{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":18,"minAge":91,"maxAge":66,"enrollmentInfo":92,"targetDuration":4,"studyType":24,"phases":94,"briefSummary":95,"conditions":96,"keywords":101,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":57},"100553904","myofascial-release-technique-in-women-with-primary-dysmenorrhea-100553904","NCT06492148","Myofascial Release Technique in Women With Primary Dysmenorrhea","Effect of Myofascial Release Technique on Central Sensitization, Myofascial Trigger Point and Menstrual Symptoms in Women With Primary Dysmenorrhea: Sham-Controlled, Randomized Double-Blind Study","Inclusion Criteria:\n\n* Diagnosed with Primary Dysmenorrhea according to the Primary Dysmenorrhea Consensus Guide,\n* Having regular menstruation in the last 6 months (28±7 days)\n* Those who had menstrual pain between 40 mm and 100 mm according to the Visual Analogue Scale (VAS) in the last 6 months\n\nExclusion Criteria:\n\n* Diagnosed with Secondary Dysmenorrhea,\n* Having given birth,\n* Those with serious gastrointestinal, urogynecological, or autoimmune diseases or other chronic pain syndromes,\n* Undergoing urogynecological surgery,\n* Those who are pregnant or suspected of pregnancy,\n* Those who use analgesics or non-pharmacological agents other than NSAIDs for menstrual pain,\n* Those using intrauterine or oral contraceptives,\n* Those taking extra supplements such as magnesium, which may affect treatment","18 Years",{"count":93,"type":23},36,[26],"It has been found that women with dysmenorrhea have active trigger points, particularly in the rectus abdominis, oblique abdominal muscles, quadratus lumborum, and paraspinal muscles. The myofascial release technique is a widely used manual therapy method characterized by the application of low-load, long-duration mechanical forces to manipulate the myofascial complex. This technique aims to restore optimal length, alleviate pain, and improve function. This study aims to examine the effect of the myofascial release technique on central sensitization, myofascial trigger points, and menstrual symptoms in women with primary dysmenorrhea.",[97,98,99,33,100],"Dysmenorrhea Primary","Central Sensitisation","Myofascial Trigger Point Pain","Myofascial Release",[102,103,104,29,105],"myofascial release","trigger point","Central sensitization","sham","RECRUITING","2024-11-19",{"date":109,"type":49},"2024-11-21",{"date":111,"type":49},"2024-09-10",{"date":113,"type":23},"2025-09-25",{"name":115,"class":56},"Gazi University"]